China's transcatheter aortic valve replacement (TAVR) is developing rapidly, with the domestic annual procedure volume reaching 12,000 cases in 2023, a year-on-year increase of 40%, and it is expected to exceed 15,000 cases in 2024. Currently, more than 300 hospitals across the country have performed TAVR procedures, covering all provincial-level administrative regions, with technology adoption accelerating from first-tier cities to second- and third-tier cities.
Significant breakthroughs have been made in domestic valve development, such as VenusA series by Venus Medtech and VitaFlow series by MicroPort, which have captured a dominant share of the domestic market and are gradually expanding internationally. Meanwhile, international giants Edwards Lifesciences and Medtronic have also increased their presence in China, promoting technological exchange and innovation.
Background and Significance
Aortic stenosis is a common heart valve disease in the elderly. Traditional surgical valve replacement is highly invasive and carries significant risks, leading many elderly patients to forgo treatment due to intolerance. TAVR, as a minimally invasive interventional technique, implants an artificial valve via the femoral artery or apical approach without the need for open-heart surgery, resulting in faster recovery and significantly lowering the threshold for treatment.
With the acceleration of population aging in China, the prevalence of aortic stenosis among people aged 60 and above is approximately 3%-5%, with an estimated total patient population exceeding 4 million. The widespread adoption of TAVR fills the treatment gap for elderly high-risk patients and holds great significance for improving national cardiovascular health.
Significance for International Patients
For international patients, China's TAVR technology offers significant advantages: first, the procedure cost is far lower than in Western countries, averaging about one-third of the cost in the United States; second, waiting times are short, with procedures typically scheduled within 2 weeks; third, domestic valves are designed to better suit the anatomical structure of Asian populations, yielding favorable clinical outcomes.
Additionally, many Chinese hospitals, such as Shanghai Partner Hospitals, have accumulated extensive experience in TAVR, with annual procedure volumes exceeding 100 cases each, and are equipped with international-standard hybrid operating rooms and postoperative monitoring systems, providing high-quality services to international patients.
How MedCare Can Help
MedCare, as a cross-border medical platform, provides comprehensive support for international patients planning to undergo TAVR treatment in China. Our partner medical institutions include top cardiovascular centers in Shanghai, Beijing, Guangzhou, and other cities, all with mature TAVR teams and advanced equipment.
Patients can learn about treatment costs through Cost Estimator, and our medical consultants will assist in arranging preoperative assessments, visa processing, translation accompaniment, and postoperative follow-up, ensuring a smooth and worry-free treatment process. Visit the Medical Services page for more details, or contact us via Contact Us for personalized plans.
Related Reading: Overview of Shanghai Partner Hospitals